Consenso intersocietario* sobre tratamiento y seguimiento de pacientes con cáncer diferenciado de tiroides

La incidencia del cancer diferenciado de tiroides se incremento exponencialmente en todo el mundo. Aunque estos tumores presentan un pronostico excelente, se produjeron multiples cambios en el enfoque terapeutico y de seguimiento en los ultimos anos. Esta situacion, vinculada principalmente con la estadificacion por riesgos de recurrencia de la enfermedad, determino la necesidad de generar un consenso entre representantes de las 3 sociedades argentinas que habitualmente se encuentran involucradas en el manejo de estos pacientes, (Sociedad Argentina de Endocrinologia y Metabolismo, Asociacion Argentina de Cirugia de Cabeza y Cuello y Asociacion Argentina de Biologia y Medicina Nuclear). Las recomendaciones se realizaron de acuerdo a la experiencia de los participantes y a la revision de la literatura. Rev Argent Endocrinol Metab 52:85-118, 2014 Conflictos de interes: Pitoia F: Consultoria, Advisory Board, Speaker Genzyme-Sanofi; Consultoria, Advi­sory Board, Speaker, Steering Committee Bayer; Consultoria, Advisory Board, Speaker Astra Zeneca. Califano I: Speaker Genzyme-Sanofi; Consultoria, Advisory Board, Speaker AstraZeneca. Faure E: Consultoria, Advisory Board, Speaker Genzyme-Sanofi; Consultoria, Advisory Board, Speaker AstraZeneca. Gauna A: Advisory Board Genzyme-Sanofi.; Advisory Board Bayer. Mollerach A: Advisory Board Genzyme-Sanofi. Orlandi A: Advisory Board, Speaker Genzyme-Sanofi. El resto de los autores no declaran conflictos de intereses.(AU) The incidence of differentiated thyroid cancer increased exponentially worldwide. Although these tumors usually have an excellent prognosis, multiple changes occurred in the therapeutic approach and follow-up in recent years. This situation, mainly related to the stratification by the risk of recurrence of the disease, made it necessary to build a consensus among representative members from the three Argentinean societies that are usually involved in the management of these patients, (Argentinean Society of Endocrinology and Metabo lism, Argentinean Association of Head and Neck Surgery and Argentinean Association of Biology and Nuclear Medicine). The recommendations were done according to personal experiences and review of bibliography. Rev Argent Endocrinol Metab 52:85-118, 2014 Conflicts of interest: Pitoia F: Consultancy, Advisory Board, Speaker Genzyme-Sanofi; Consultancy, Advisory Board, Speaker, Steering Committee Bayer; Consultancy, Advisory Board, Speaker AstraZeneca. Califano I: Speaker Genzyme-Sanofi; Consultancy, Advisory Board, Speaker AstraZeneca. Faure E: Consultancy, Advisory Board, Speaker Genzyme-Sanofi; Consultancy, Advisory Board, Speaker AstraZeneca. Gauna A: Advisory Board Genzyme-Sanofi.; Advisory Board Bayer. Mollerach A: Advisory Board Genzyme-Sanofi.Orlandi A: Advisory Board, Speaker Genzyme-Sanofi. No other financial conflicts of interest exist.(AU)